for Veterans and the Public
Chronic Hepatitis C Virus (HCV) Infection: Treatment Considerations
For the full PDF version, click here
This revision (September 22, 2016) incorporates updates to treatment regimens for chronic hepatitis C virus (HCV) infection, genotype 1, 2, 3, or 4. Updated sections include:
- A revised table in "Interpretation of Resistance-Associated Polymorphisms"
- A new table for "Genotype 1-Infected Patients Who Have Failed Treatment with DAA-Based Therapy"
- Updates on drug-drug interactions to provide clinicians with guidance on the concomitant use of HCV drugs and other drugs, including HIV antiretroviral agents (Table 25 and Table 26)
- Information on HCV resistance genotyping and sample reports can be found in Appendices B and C
The Panel continues to recommend that HIV/HCV-coinfected patients receive the same HCV antiviral regimens as HCV-monoinfected patients except in situations where ledipasvir/sofosbuvir is being considered, in which case a 12-week regimen should be used.